DeDora Capital Inc. Sells 998 Shares of Gilead Sciences, Inc. (GILD)

DeDora Capital Inc. lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 14.9% in the third quarter, according to its most recent filing with the SEC. The fund owned 5,689 shares of the biopharmaceutical company’s stock after selling 998 shares during the period. DeDora Capital Inc.’s holdings in Gilead Sciences were worth $439,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Bank of New York Mellon Corp lifted its holdings in shares of Gilead Sciences by 11.6% in the second quarter. Bank of New York Mellon Corp now owns 30,936,970 shares of the biopharmaceutical company’s stock valued at $2,191,575,000 after purchasing an additional 3,221,439 shares in the last quarter. Swedbank lifted its holdings in shares of Gilead Sciences by 103.7% in the third quarter. Swedbank now owns 3,906,172 shares of the biopharmaceutical company’s stock valued at $301,596,000 after purchasing an additional 1,988,987 shares in the last quarter. Natixis lifted its holdings in shares of Gilead Sciences by 4,550.6% in the second quarter. Natixis now owns 1,913,535 shares of the biopharmaceutical company’s stock valued at $135,555,000 after purchasing an additional 1,872,389 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. lifted its holdings in shares of Gilead Sciences by 1,631.7% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 997,656 shares of the biopharmaceutical company’s stock valued at $70,674,000 after purchasing an additional 940,044 shares in the last quarter. Finally, Sanders Capital LLC lifted its holdings in shares of Gilead Sciences by 7.0% in the second quarter. Sanders Capital LLC now owns 10,579,575 shares of the biopharmaceutical company’s stock valued at $804,126,000 after purchasing an additional 696,200 shares in the last quarter. Institutional investors own 78.06% of the company’s stock.

NASDAQ GILD opened at $73.27 on Friday. Gilead Sciences, Inc. has a 1-year low of $64.27 and a 1-year high of $89.54. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.92 and a current ratio of 3.00. The firm has a market capitalization of $96.15 billion, a PE ratio of 10.67, a P/E/G ratio of -3.77 and a beta of 1.01.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.56 by $0.35. Gilead Sciences had a net margin of 9.52% and a return on equity of 41.57%. The business had revenue of $5.65 billion for the quarter, compared to the consensus estimate of $5.20 billion. During the same period in the prior year, the business posted $2.56 earnings per share. Gilead Sciences’s revenue for the quarter was down 20.9% compared to the same quarter last year. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 6.56 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Thursday, September 27th. Stockholders of record on Friday, September 14th were paid a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.11%. The ex-dividend date of this dividend was Thursday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 26.64%.

A number of research firms have recently issued reports on GILD. BidaskClub upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, July 10th. ValuEngine lowered Gilead Sciences from a “hold” rating to a “sell” rating in a report on Monday, August 20th. Mizuho set a $94.00 target price on Gilead Sciences and gave the company a “buy” rating in a report on Tuesday, July 31st. Zacks Investment Research lowered Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 25th. Finally, Robert W. Baird lowered Gilead Sciences from an “outperform” rating to a “neutral” rating and set a $79.00 target price for the company. in a report on Thursday, July 26th. Eleven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and a consensus price target of $87.85.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the stock in a transaction on Monday, October 1st. The shares were sold at an average price of $78.04, for a total transaction of $3,902,000.00. Following the transaction, the director now directly owns 3,067,762 shares of the company’s stock, valued at $239,408,146.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 150,000 shares of company stock worth $11,502,500 over the last ninety days. 1.30% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

See Also: Initial Public Offering (IPO)

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply